Hosted on MSN1mon
Entero Therapeutics names Richard Paolone interim CEOEntero Therapeutics, Inc. (NASDAQ ... amounting to approximately $7.4 million. The company contests the existence of any default related to the financial statements and is exploring strategic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback